• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TGTX

TGTX

TG Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD40.11

+3.47 (+9.47%)

Rating:B+

Company Profile

CEO

Michael S. Weiss

IPO Date

2010-05-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$38.65

Prev. Close

$36.64

Day Low

$37.96

Day High

$41.34

52W Low

$25.28

52W High

$44.65

Market Cap

$6.14B

Volume

3.62M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

20.0%

Avg Negative

2.4%

Avg Neutral

77.2%

News Feed

TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update

GlobeNewsWire·7/28/2021·↓ negative

TG Therapeutics: Continuing To Deliver

Seeking Alpha·7/12/2021·↑ positive

TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

GlobeNewsWire·7/9/2021·↓ negative

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology

GlobeNewsWire·6/18/2021·↑ positive

TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma

GlobeNewsWire·6/18/2021·↑ positive

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

GlobeNewsWire·6/11/2021·↑ positive

TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma

GlobeNewsWire·6/9/2021·↓ negative

TG Therapeutics to Present at Upcoming Investor Conferences

GlobeNewsWire·5/27/2021·↑ positive

TGTX Stock Price: Over 7% Increase Pre-Market Explanation

Pulse2·5/25/2021·↑ positive

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

GlobeNewsWire·5/25/2021·↓ negative